FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
All XRAYs
Relevance: Medium


Article : Breast cancer risk for transgender women with inherited mutations
Relevance: Medium


Most relevant for: Transgender women with inherited mutations who are considering or have had gender affirming care
There has been little research on breast cancer risk for transgender women who are at high risk for breast cancer due to an inherited mutation. This review summarizes what we know. (Posted 11/29/23)
Este artículo está disponible en español.
Read More
Relevance: High


Quality of Writing: High


Article : Signs of endometrial cancer: Six survivor stories
Relevance: High


Quality of Writing: High


Most relevant for: Women who want to learn more about the signs of or are at risk for endometrial cancer.
This article shares the experiences of six women diagnosed with endometrial cancer. It highlights the most common signs of endometrial cancer. (Posted 11/16/23)
Este artículo está disponible en español.
Read More
Relevance: Medium-High


Research Timeline: Post Approval


Update : New drug combination approved for treatment of BRCA-mutated metastatic prostate cancer
Most relevant for: People with metastatic castration resistant prostate cancer with a mutation in BRCA1 or BRCA2
The FDA approved Akeega (niraparib and abiraterone) plus prednisone for the treatment of BRCA-mutated, metastatic castration-resistant prostate cancer (mCRPC). Akeega can be used as an early or later treatment. (Posted 11/9/23)
Este artículo está disponible en español.
Read More
Relevance: Medium-High


Strength of Science: Medium-High


Research Timeline: Post Approval


Study : Pausing hormone therapy to pursue pregnancy does not increase the short-term risk of early-stage cancer recurrence
Relevance: Medium-High


Strength of Science: Medium-High


Research Timeline: Post Approval


Most relevant for: Women with breast cancer who are considering pregnancy
Women who paused hormone therapy treatment of early-stage hormone receptor-positive (HR-positive) breast cancer to attempt to get pregnant had no increase in short-term recurrence. (Posted 11/3/23)
Este artículo está disponible en español.
Read More
Relevance: Medium-High


Strength of Science: Medium-High


Article : Red flags for colorectal cancer in young adults
Most relevant for: Young adults
The rate of colorectal cancer in young adults has been increasing. Researchers in this study identified four signs or “red flags” for colorectal cancer before age 50 (considered to be early onset colorectal cancer). Recognizing these red flags can help diagnose and treat colorectal cancer earlier. (Posted 10/23/23)
Este artículo está disponible en español.
Read More
Relevance: Medium-High


Research Timeline: Post Approval


Update : New first-line treatment option for metastatic prostate cancer
Most relevant for: People with metastatic castration resistant prostate cancer who have an inherited or tumor mutation in certain genes.
The FDA has approved Talzenna (talazoparib) with Xtandi (enzalutamide) as first-line treatments for some patients with metastatic castration-resistant prostate cancer. (Posted 10/2/23)
Este artículo está disponible en español.
Read More
Relevance: Medium-High


Research Timeline: Human Research


Article : Artificial intelligence (AI) may find breast cancer on mammograms sooner
Most relevant for: People interested in the use of artificial intelligence in medicine
Artificial intelligence (AI) tools may help doctors read mammograms. This assistance may lead to earlier diagnoses of breast cancer. (Posted 9/29/23)
Este artículo está disponible en español.
Read More
Relevance: High


Quality of Writing: Medium-High


Article : Genetic testing and the future of medicine
Relevance: High


Quality of Writing: Medium-High


Most relevant for: People interested in genetic testing.
An article published in Katie Couric Media discusses genetic testing and how it can impact health. The author talked with Dr. Robert Steiner, a doctor who specializes in genetics. He talked about genetic testing and how the results can affect health and change lives. (Posted 9/28/23)
Este artículo está disponible en español.
Read More
Relevance: Medium-High


Quality of Writing: High


Topic : Sexual health concerns of gay and bisexual men with prostate cancer
Relevance: Medium-High


Quality of Writing: High


Most relevant for: Gay and bisexual men diagnosed with prostate cancer
Prostate cancer therapy can affect gay and bisexual men differently than heterosexual men. Many urologists do not routinely address these unique concerns. Selecting providers who understand the concerns that are unique to gay and bisexual patients and asking questions about sexual health concerns may improve these patients' healthcare experiences. (Posted 9/21/23)
Este artículo está disponible en español.
Read More
Relevance: Medium-High


Research Timeline: Post Approval


Update : New drug combination for early treatment of some metastatic prostate cancer
Most relevant for: People with metastatic castration resistant prostate cancer with a mutation in BRCA1 or BRCA2
The FDA approved Lynparza (olaparib) for use earlier in treatment of metastatic castration-resistant prostate cancer (mCRPC) when added to abiraterone and prednisone for people with a BRCA mutation found through genetic or tumor testing. Lynparza combined with hormone therapy may now be used as a first-line or later treatment. (Posted 9/11/23)
Este artículo está disponible en español.
Read More